Calamos Advisors
IQMD

Calamos Advisors’s Intelligent Medicine Acquisition Corp. Class A Common Stock IQMD Stock Holding History

Calamos Advisors’s Portfolio IQMD Stock Details IQMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,250,000
Closed -$12.8M – 1262
2022
Q4 		$12.8M Buy
+1,250,000
New +$12.7M 0.06% 377

Other funds holding IQMD

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

Calamos Advisors's IQMD Position: Q1 2023 in Review

Calamos Advisors sold out of Intelligent Medicine Acquisition Corp. Class A Common Stock (IQMD) in Q1 2023, closing a stake of 1,250,000 shares — an estimated $12.8M sold.

Calamos Advisors first reported a position in IQMD in Q4 2022 and held it in 1 quarter. The position peaked at $12.8M in Q4 2022. 8 funds tracked by Wall St. Rank hold IQMD as of Q1 2023.

  • Calamos Advisors reported no remaining Intelligent Medicine Acquisition Corp. Class A Common Stock position as of Q1 2023 after selling out during the quarter.
  • Calamos Advisors sold 1,250,000 Intelligent Medicine Acquisition Corp. Class A Common Stock shares in Q1 2023, an estimated $12.8M.
  • Calamos Advisors first reported a position in Intelligent Medicine Acquisition Corp. Class A Common Stock in Q4 2022 and held it in 1 quarter.
  • Calamos Advisors's Intelligent Medicine Acquisition Corp. Class A Common Stock position peaked at $12.8M in Q4 2022.
  • 8 funds tracked by Wall St. Rank held Intelligent Medicine Acquisition Corp. Class A Common Stock as of Q1 2023.

Based on Calamos Advisors's 13F filing for Q1 2023, filed 4 May 2023.